There are a lot of major biotech events on the horizon at which Midwestern biotech firms can strut their stuff, but the region has to think of its place on the global stage, according to columnist Michael Rosen. In this edition of Yer Biotech Blues,...
Althea Technologies has been chosen by Madison's Quintessence Biosciences to produce its lead protein oncology drug for forthcoming clinical trials. The drug candidate, QBI-139, has proven to be effective in fighting cancer in various solid tumors and soon may be the subject of clinical trials. ...
What's an investor to do when assessing the prospects of a promising new biotechnology? In this WTN guest column, former University of Wisconsin-Madison professor and medical researcher Steve Clark provides the right question to ask, and it has more to do with assessing risk than...
Biotechnology and healthcare industry veteran Noel Doheny is the new chief executive officer for OpGen, Inc., a Madison-based company that provides DNA analysis for infectious disease management. The company, which is commercializing a DNA analysis technology known as optical mapping, cited Doheny's ability to commercialize...
Although the IPOs of Midwest life-science companies (such as TomoTherapy) do not yet position them as large-cap companies, the large amount of funding they received is encouraging for the Midwest, according to columnist Michael Rosen. In this edition of Yer Biotech Blues, Rosen says the...
President Bush, in his last State of the Union address, not only praised a recent discovery that produces adult cells that act as human embryonic stem cells without destroying embryos, he urged assembled members of Congress to expand funding for such research. Bush already has...
Citing increased membership, the Wisconsin Biotechnology and Medical Device Association, which represents the state's bioscience industry, has moved its headquarters to University Research Park in Madison. The organization's membership had grown from 46 companies in 2001 to 225 by the end of 2007. ...
James Thomson, the University of Wisconsin-Madison stem cell researcher, says Wisconsin will have to invest $50 million annually to keep pace, on a per capita basis, with stem cell investments being made by the State of California. Thomson, speaking at the monthly WIN-Madison luncheon, said...
The Food and Drug Administration has cleared for marketing a new test for respiratory viruses manufactured by the Milwaukee-based Prodesse, Inc. ProFlu, a molecular biology device, detects four viruses, including influenza, and according to the company, produces results either faster or more accurately than other...
Nerites has received a $100,000 grant from the National Institutes of Health to study new treatments for preventing bacterial infections on urinary stents and catheters. Urinary stents and catheters can be life-saving medical devices, but biofilm growth can cause 40 percent of patients to develop...